|
Aug 14
|
Liberty All-Star® Growth Fund, Inc. July 2025 Monthly Update
|
|
Aug 14
|
5 Revealing Analyst Questions From Natera’s Q2 Earnings Call
|
|
Aug 13
|
1 ‘Strong Buy’ Stock Analysts Think Will Soar 62%
|
|
Aug 12
|
NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures
|
|
Aug 11
|
Natera And 2 Other Stocks That May Be Priced Below Their Estimated Value
|
|
Aug 9
|
Natera Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Aug 8
|
Why Are Natera (NTRA) Shares Soaring Today
|
|
Aug 8
|
Wall Street Set to Open Slightly Higher Friday as Investors Pore Over Earnings Results
|
|
Aug 8
|
Investors Parse, Look Ahead to Earnings Announcements as US Futures Rise Friday Pre-Bell
|
|
Aug 8
|
Natera introduces prenatal test for detecting inherited conditions
|
|
Aug 8
|
Natera (NASDAQ:NTRA) Delivers Strong Q2 Numbers, Stock Jumps 12.6%
|
|
Aug 7
|
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics
|
|
Aug 7
|
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 7
|
Natera: Q2 Earnings Snapshot
|
|
Aug 7
|
Natera Reports Second Quarter 2025 Financial Results
|
|
Aug 7
|
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
|
|
Aug 6
|
What To Expect From Natera’s (NTRA) Q2 Earnings
|
|
Jul 29
|
Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
|
|
Jul 28
|
Non-Invasive Prenatal Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Eurofins Scientific, F. Hoffmann-La Roche, Invitae, Illumina, Natera, Centogene, and Qiagen
|
|
Jul 24
|
PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
|